Almac increases commercial sacheting capacity

Published: 14-Jun-2010 Featured companies: Almac Group
Packaging Finance

Completes client sponsored investment of £2m at its hq in Northern Ireland

Almac Pharma Services has installed dispensing and blending suites, a sachet filling and packaging line and supporting storage and wash areas in a client sponsored capital investment of £2m at its headquarters in Craigavon, Northern Ireland.

The new 5,500ft2 facility accommodates 2.5 tonne batches and annualised output will be in excess of 120 million sachets, split across various packed formats.


Geoff Sloan, vice president of manufacturing operations at Almac Pharma Services, said: ‘This investment has allowed our client to meet growing demand for one of its key future products.’

Graeme McBurney, president and managing director of Almac Pharma Services, added: ‘This level of investment demonstrates our commitment to building long term, strategic relationships with our client partners.’

Featured companies

The Almac Group is an established contract development and manufacturing organisation which provides an extensive range of integrated services to the pharmaceutical and biotech...
See more

You may also like

Research & Development

Almac Group announces £11m investment to expand global analytical services

Read more
The Almac Group has announced an £11m investment and the creation of more than 100 new jobs to expand its global analytical services capabilities

Trending Articles

  1. Vetter strengthens senior management team for growth Three new managing directors to support global sustainable development
  2. Dual-chamber packaging systems as a simplification factor in the supply chain Dual-chamber packaging solutions could represent a new frontier also to package parenteral drugs, simplifying the supply chain through reconstitution, potentially making logistics more flexible and efficient, says Cecilia Bassi, Product Manager at Bormioli Pharma
  3. AstraZeneca to stop production of Pulmicort pMDI Agreements with SkyePharma expected to be terminated
  4. Merck attains $588m global license for PD-1/VEGF bispecific antibody from LaNova Medicines The bispecific antibody is designed for oncological indications and functions by inhibiting the PD-1/PD-L1 and the VEGF/VEGFR receptor signalling pathways

Relevant companies

See more

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

You may also like

Research & Development

Almac Group announces £11m investment to expand global analytical services

The Almac Group has announced an £11m investment and the creation of more than 100 new jobs to expand its global analytical services capabilities
Manufacturing

Almac Sciences awarded Life Sciences Innovative Manufacturing Fund grant

Grant awarded to support the expansion of Almac’s small molecule API manufacturing plant
Design & Build

Almac expands manufacturing, packaging and peptide production capacity with purpose-built facilities

Ongoing Global expansion investment now totals more than £400m
Manufacturing

Almac Group releases details of $97m HQ expansion in Northern Ireland

The £80 million expansion has been designed by the pharmaceutical services provider to provide a 140,000 sqft capacity increase for development and manufacturing facilities
Finance

Almac records highest ever revenue, profit and employee numbers as £200 million global expansion plans announced

Almac Group, the global contract pharmaceutical development and manufacturing organisation, has reported its highest ever end-of-year results for revenue, profit and employee numbers.
Finance

Almac to create 1800 jobs across global sites

These jobs include operational, supervisory and managerial roles across its business and offer opportunities for both graduates and experienced candidates alike
Finance

Almac Group invests in continuous flow manufacturing

The custom and flow chemistry team can rapidly screen processes to demonstrate reaction validity under continuous flow
Subscribe now